Patents by Inventor Jayaprakash Pagadala
Jayaprakash Pagadala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230041951Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: March 14, 2022Publication date: February 9, 2023Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Christopher C. Coss, James T. Dalton, Charles B. Duke
-
Patent number: 11273147Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: August 30, 2019Date of Patent: March 15, 2022Assignee: University of Tennessee Research FoundationInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Christopher C. Coss, James T. Dalton, Charles B. Duke
-
Publication number: 20200222365Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: August 30, 2019Publication date: July 16, 2020Applicant: Oncternal Therapeutics, Inc.Inventors: Ramesh NARAYANAN, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Christopher C. Coss, James T. Dalton, Charles B. Duke
-
Patent number: 10441570Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: May 16, 2018Date of Patent: October 15, 2019Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton
-
Patent number: 10369133Abstract: Here provided are new immunosuppressive compounds and novel therapeutics for improving tissue transplantation.Type: GrantFiled: July 23, 2014Date of Patent: August 6, 2019Assignee: THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Duane Douglas Miller, Charles Ryan Yates, Jayaprakash Pagadala, Ram Mahato, Hao Wu
-
Publication number: 20180360805Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: May 16, 2018Publication date: December 20, 2018Applicants: GTx, Inc., University of Tennessee Research FoundationInventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE, Jayaprakash PAGADALA, Charles B, DUKE, Christopher C. COSS, James T. DALTON
-
Patent number: 10035763Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: October 21, 2016Date of Patent: July 31, 2018Assignee: GTX, INC.Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
-
Patent number: 10017471Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: July 28, 2016Date of Patent: July 10, 2018Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
-
Patent number: 9834525Abstract: This disclosure relates to small molecule inhibitors of paxillin and paxillin binding, and related compositions and methods of treatment.Type: GrantFiled: February 4, 2015Date of Patent: December 5, 2017Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Charles Ryan Yates, Duane D. Miller, Frank Park, Jordan J. Toutounchian, Vanessa Morales-Tirado, Shivaputra Patil, Jayaprakash Pagadala, Bilal Abou Aleiwi
-
Patent number: 9814698Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: April 21, 2016Date of Patent: November 14, 2017Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
-
Publication number: 20170166526Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: October 21, 2016Publication date: June 15, 2017Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
-
Publication number: 20170095446Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: April 21, 2016Publication date: April 6, 2017Applicants: GTx, Inc., University of Tennessee Research FoundationInventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin Hwang, Jayaprakash PAGADALA, Charles B. DUKE, Christopher C. COSS, James T. DALTON, Yali HE
-
Publication number: 20170029370Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: July 28, 2016Publication date: February 2, 2017Inventors: Ramesh Narayanan, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin Hwang, Jayaprakash PAGADALA, Charles B. DUKE, Christopher C. COSS, James T. DALTON, Yali HE
-
Publication number: 20160347725Abstract: This disclosure relates to small molecule inhibitors of paxillin and paxillin binding, and related compositions and methods of treatment.Type: ApplicationFiled: February 4, 2015Publication date: December 1, 2016Inventors: Charles Ryan Yates, Duane D. Miller, Frank Park, Jordan J. Toutounchian, Vanessa Moraies-Tirado, Shivaputra Patil, Jayaprakash Pagadala, Bial Abou Aleiwi
-
Publication number: 20120329879Abstract: Provided herein are methods for improving function in a retinal cell associated with a diabetic condition and for treating a diabetic retinopathic condition in a subject. The methods comprise contacting the retinal cell or administering to the subject a beta-adrenergic receptor agonist or R-isomer thereof such as have the chemical structural formula: where R1 is (CH2)n(CH3)2 or where n is 1 to 4, R2 is H or H.HX, where X is a halide and R3 is O(CH2)mCH3 at one or more of C2-C6, where m is 0 to 4. Also provided are BAR agonists having the structural where R1 is the (CH2)n-phenyl-R2 substituent and the hydroxy-benzene moiety is 1,2-benzene diol or 1,3-benzene diol.Type: ApplicationFiled: September 7, 2012Publication date: December 27, 2012Applicant: THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Jena J. Steinle, Kimberly P. Williams, Jayaprakash Pagadala, Duane D. Miller
-
Patent number: 7001982Abstract: Nonnatural C-linked carbo-?-peptides with robust secondary structures, which involves the synthesis of a new class of ?-peptides called C-linked carbo-?-peptides. The compounds are favorably disposed for the formation of stable helical structures and are useful as biologically active carbo-?-peptides. The new class of ?-peptides have the following formula The new class of ?-peptides are useful as biologically active molecules to disrupt biological interactions of proteins, for molecular design and to synthesize peptide libraries.Type: GrantFiled: March 31, 2003Date of Patent: February 21, 2006Assignee: Council of Scientific and Industrial ResearchInventors: Gangavaram Vasantha Madhava Sharma, Kondireddi Ravinder Reddy, Radha Krishna Palakodety, Ajit Chand Kunwar, Ravi Sankar Ampapathi, Jagannadh Bulusu, Jayaprakash Pagadala
-
Publication number: 20040192885Abstract: This invention relates to Novel nonnatural C-linked carbo-&bgr;-peptides with robust secondary structures, which comprises the synthesis of a new class of &bgr;-peptides called C-linked carbo-&bgr;-peptides, most of which are favorably disposed for the formation of stable helical structures.Type: ApplicationFiled: March 31, 2003Publication date: September 30, 2004Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Gangavaram Vasantha Madhava Sharma, Kondireddi Ravinder Reddy, Radha Krishna Palakodety, Ajit Chand Kunwar, Ravi Sankar Ampapathi, Jagannadh Bulusu, Jayaprakash Pagadala